Ventilation Associated Pneumonia and Covid-19

COVID-19 Clinical Trial

— ECOLCOVID  

Official title:

Ventilator-associated Pneumonia Ecology Comparison in a French ICU Center NIMES Between First and Second Wave of COVID-19 : a Retrospective Monocentric Descriptive Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05089968
• Other study ID #: LOCAL/2021/LC-01
• Status: Completed
• Start date: January 24, 2020
• Est. completion date: January 8, 2021

Study information

• Verified date: October 2021
• Source: Centre Hospitalier Universitaire de Nimes
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In December 2019, a new pandemic emerged, the COVID-19 disease caused by a SARS-Cov-2 virus. One of the most common symptoms of COVID-19 is mainly respiratory failure and patients requires assistance by mechanical ventilation. Ventilator-associated pneumonia (VAP) is a risk of this assistance. Since the beginning of the pandemic, Standard of care have evolved with new data. The prevalence of these VAPs seems significantly higher in the population of patients with ARDS COVID-19 (40-50%) and their ecology seems to have evolved over time, particularly in terms of bacterial resistance. Investigators want to describe and compare this evolution of bacterial and fungal ecology as well as identify potential risk factors that may be associated with these changes in ecology during different waves.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 268
• Est. completion date: January 8, 2021
• Est. primary completion date: January 8, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age > 18 years
• Positive SARS-Cov-2 polymerase chain reaction (PCR)
• healthcare associated pneumonia Exclusion Criteria : Patient opposition to participate to the study

Related Conditions & MeSH terms

• Ards
• COVID-19
• Pneumonia
• Pneumonia, Ventilator-Associated
• SARS-CoV2 Infection
• Ventilator Associated Pneumonia

Locations

Country	Name	City	State
France	CHU de Nîmes - Hôpital Universitaire Carémeau	Nîmes Cedex 09

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Nimes

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	VAP ecological difference between the first and second waves of COVID	Proportion of patients admitted to critical care with documented multidrug-resistant bacteria (MDR) VAP in Covid-19 wave 1 and 2	January 2020 to January 2021
Secondary	proportion of fungal co-infections	Comparison of the proportion of patients with a fungal infection during the 1st and 2nd wave	January 2020 to January 2021
Secondary	duration of mechanical ventilation	Number of days under mechanical ventilations	Day 28
Secondary	number of days of organ failure	number of days between first organ failure and no organ failure (discharge from intensive care)	Day 28
Secondary	Mortality	proportion of patients deceased at day 28	Day 28
Secondary	proportion of patients treated with corticosteroid therapy	proportion of patients treated with corticosteroid therapy	Day 28
Secondary	probabilistic antibiotic therapy at admission	probabilistic antibiotic therapy prescribed at admission	Day 1
Secondary	antiviral treatment	proportion of patients treated with antiviral treatment	Day 28